Medline (NASDAQ:MDLN – Get Free Report) and Insulet (NASDAQ:PODD – Get Free Report) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, earnings, institutional ownership, risk and valuation.
Valuation & Earnings
This table compares Medline and Insulet”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Medline | $28.43 billion | 1.80 | $1.16 billion | $0.44 | 88.44 |
| Insulet | $3.19 billion | 3.17 | $247.10 million | $6.14 | 23.72 |
Analyst Recommendations
This is a summary of current ratings and price targets for Medline and Insulet, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Medline | 2 | 4 | 23 | 0 | 2.72 |
| Insulet | 1 | 12 | 12 | 0 | 2.44 |
Medline currently has a consensus price target of $46.08, suggesting a potential upside of 18.40%. Insulet has a consensus price target of $185.67, suggesting a potential upside of 27.47%. Given Insulet’s higher probable upside, analysts plainly believe Insulet is more favorable than Medline.
Profitability
This table compares Medline and Insulet’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Medline | 1.84% | 8.21% | 4.03% |
| Insulet | 13.44% | 31.76% | 14.48% |
Summary
Insulet beats Medline on 6 of the 11 factors compared between the two stocks.
About Medline
Medline is a healthcare products manufacturer and distributor serving providers across the care continuum. Its customers include hospitals, surgery centers, physician practices, long-term care facilities and home-care organizations. The company offers a broad range of medical and surgical supplies, including products for infection prevention, wound care and patient care, as well as apparel and equipment. Medline also provides supply-chain and logistics services to healthcare organizations. Founded in 1966, Medline is headquartered in Northfield, Illinois, and serves customers in the United States and internationally.
About Insulet
Insulet Corporation is a medical device company focused on insulin delivery for people with diabetes. Founded in 2000, the company developed the Omnipod platform, which delivers insulin through a small, wearable pod without the tubing used by many traditional insulin pumps. Its products include Omnipod DASH and Omnipod 5, an automated insulin delivery system that can adjust insulin delivery based on glucose readings from compatible continuous glucose monitors. Insulet also provides related controllers, mobile app features, supplies and customer support.
Receive News & Ratings for Medline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medline and related companies with MarketBeat.com's FREE daily email newsletter.
